

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A depot system, ~~particularly for delayed release of active substances, characterized in that said system~~ comprising liposomes having a membrane, the liposomes comprising with
 - saturated synthetic phosphatidyl cholines selected from one or more from the group consisting of DMPC, DPPC and/or DSPC,
 - cholesterol with a percentage ~~of~~ ranging from 35 to 50 mole-%,
 - cationic lipids selected from the group of DC-Chol, DAC-Chol, DMTAP, DPTAP and/or DOTAP with a percentage ~~of~~ ranging from 5 to 20 mole-% in the liposomal membrane, and
 - ~~at least one protein and/or peptide active substance~~ one or more selected from the group consisting of protein and peptide active substances.
2. (currently amended) The depot system according to claim 1, ~~characterized in that~~ wherein the cationic lipids are cationic in a pH-sensitive fashion and selected from one or more from the group consisting of His-Chol and/or Mo-Chol.
3. (currently amended) The depot system according to ~~any of the preceding claims~~ claim 1, ~~characterized in that~~ wherein at least 90% of the active substance is enclosed in the liposome and less than 10% is outside the liposome.
4. (currently amended) The depot system according to ~~any of the preceding claims~~ claim 1, ~~characterized in that~~ wherein the active substance is entrapped in the liposome and more than 10% thereof is outside the liposome.
5. (currently amended) The depot system ~~for delayed release of active substances according to any of the preceding claims~~ claim 1, ~~characterized in that~~ wherein the depot system is capable of sustaining the delivery of the active substance is sustained for at least 1 week.

6. ~~(currently amended)~~ The depot system according to ~~any of the preceding claims~~ claim 1, ~~characterized in that wherein~~ the size of the liposomes varies from 20 to 1,000 nm, ~~particularly from 50 to 800 nm, and preferably from 50 to 300 nm.~~

7.-18. (canceled)

____ 19.(New) The depot system according to claim 1, wherein the size of the liposomes varies from 50 to 800 nm.

20.(New) The depot system according to claim 1, wherein the size of the liposomes varies from 50 to 300 nm.

21.(New) The depot system according to claim 1, wherein the active substance comprises one or more from the group consisting of LHRH agonists and GnRH analogs.

22.(New) The depot system according to claim 21, wherein the active substance comprises one or more from the group consisting of leuprolide, acetate, buserelin, goserelin and triptorelin.

23.(New) The depot system according to claim 1, wherein the said active substance comprises insulin.

24.(New) The depot system according to claim 1, wherein the said active substance comprises heparin.

25.(New) The depot system according to claim 1, wherein said active substance comprises antigen fragments for vaccination.

26.(New) The depot system according to claim 1, wherein the depot system is capable of a delayed release of active substance for at least one week and said active substance comprises oligonucleotides.

27.(New) The depot system according to claim 26, wherein said oligonucleotides are constituted of 5-100 from the group consisting of deoxyribonucleotides, ribonucleotides and chemically modified derivatives thereof.

- 28.(New) The depot system according to claim 26, wherein said oligonucleotides are constituted of 5-40 from the group consisting of deoxyribonucleotides, ribonucleotides and chemically modified derivatives thereof.
- 29.(New) The depot system according to claim 26, wherein said oligonucleotides are constituted of 10-25 from the group consisting of deoxyribonucleotides, ribonucleotides and chemically modified derivatives thereof.
- 30.(New) The depot system according to claim 26, wherein said oligonucleotides are present as one or more from the group consisting of a single strand, a double strand and in complex folding.
- 31.(New) The depot system according to claim 30, wherein said oligonucleotides are present as a single strand, said single strand being present as antisense oligonucleotides.
- 32.(New) The depot system according to claim 30, wherein said oligonucleotides are present as a double strand, said double strand being present as small interfering RNA, decoy oligonucleotides.
- 33.(New) The depot system according to claim 30, wherein said oligonucleotides are present in complex folding as aptamers, spieglemers.
- 34.(New) The depot system according to claim 1, wherein the depot system is capable of a delayed release of active substance for at least one week and said active substance comprises a water-soluble active substance derivative selected from one or more from the group consisting of active substances of antibiotic, antimycotic, cytostatic agents and glucocorticoids.
- 35.(New) Method of administering the depot system according to claim 1, comprising the step of injecting the depot system subcutaneously or intramuscularly.
- 36.(New) Method of administering the depot system according to claim 1, comprising the step of one or both from the group consisting of topical and local application to support healing processes.

37.(New) A Drug comprising a depot system according to claim 1.